Z-VAD-FMK (Cell permeable)
| Code | Size | Price |
|---|
| AG-CP3-0002-M001 | 1 mg | £140.00 |
Quantity:
| AG-CP3-0002-M005 | 5 mg | £580.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
Z-VAD(OMe)-FMK; Z-Val-Ala-DL-Asp(OMe)-FMK; pan-Caspase Inhibitor
Appearance:
White solid.
CAS:
187389-52-2
EClass:
32160000
Form (Short):
liquid
Handling Advice:
Keep cool and dry.
InChi:
InChI=1/C22H30FN3O7/c1-13(2)19(26-22(31)33-12-15-8-6-5-7-9-15)21(30)24-14(3)20(29)25-16(17(27)11-23)10-18(28)32-4/h5-9,13-14,16,19H,10-12H2,1-4H3,(H,24,30)(H,25,29)(H,26,31)/t14-,16?,19-/m0/s1
InChiKey:
MIFGOLAMNLSLGH-SXUUOERCBK
Long Description:
Chemical. CAS: 187389-52-2 and 634911-81-2. Formula: C22H30FN3O7. MW: 467.5. Synthetic. Cell permeable, non-selective broad-spectrum caspase inhibitor. Binds irreversibly to the catalytic site of caspase proteases. The peptide is O-methylated in the P1 position on aspartic acid, providing enhanced stability and increased cell permeability. Inhibits ICE-family protease/caspase processing, leading to apoptosis and autophagy induction. Decreases proteasome activity. Potent inhibitor of caspase-1 activation in NLRP3/NALP3-induced cells. Used in apoptosis and inflammasome studies.
MDL:
MFCD02684037
Molecular Formula:
C22H30FN3O7
Molecular Weight:
467.5
Other data:
Prepare a 10mM stock solution of the caspase inhibitor in high quality DMSO. Add 2µl of stock solution to 1ml of culture medium containing cells to give 20µM final concentration. Effective final concentrations are estimated to be 5-20µM. If a particular inhibitor is applied at higher concentrations, specificity for an individual caspase or even for the caspase family (>100µM) might be compromised. DMSO concentrations above 0.2% may cause cellular toxicity, thus masking the effect of the caspase inhibitor. For in vivo experiments extending 12 to 48 hours, fresh inhibitor may have to be added (injected) due to inactivation by reaction with cysteine protease.
Package Type:
Vial
Product Description:
Cell permeable, non-selective broad-spectrum caspase inhibitor [1, 3, 7, 8]. Binds irreversibly to the catalytic site of caspase proteases [1]. The peptide is O-methylated in the P1 position on aspartic acid, providing enhanced stability and increased cell permeability [1]. Inhibits ICE-family protease/caspase processing, leading to apoptosis and autophagy induction [2-4, 6, 9]. Decreases proteasome activity [5]. Potent inhibitor of caspase-1 activation in NLRP3/NALP3-induced cells [10]. Used in apoptosis and inflammasome studies.
Purity:
>95% (HPLC)
Sequence:
Z-Val-Ala-DL-Asp(OMe)-fluoromethylketone
SMILES:
[H][C@](NC(=O)OCC1=CC=CC=C1)(C(C)C)C(=O)N[C@@H](C)C(=O)NC(CC(=O)OC)C(=O)CF
Solubility Chemicals:
Soluble in DMSO, acetonitrile or dimethyl formamide.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 3 years after receipt when stored at -20°C.
References
Benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone (Z-VAD.FMK) inhibits apoptosis by blocking the processing of CPP32: E.A. Slee, et al.; Biochem. J. 315, 21 (1996) | Different interleukin-1 beta converting enzyme (ICE) family protease requirements for the apoptotic death of T lymphocytes triggered by diverse stimuli: A. Sarin, et al.; J. Exp. Med. 184, 2445 (1996) | Processing/activation of at least four interleukin-1beta converting enzyme-like proteases occurs during the execution phase of apoptosis in human monocytic tumor cells: M. MacFarlane, et al.; J. Cell Biol. 137, 469 (1997) | Processing/activation of caspases, -3 and -7 and -8 but not caspase-2, in the induction of apoptosis in B-chronic lymphocytic leukemia cells: D. King, et al.; Leukemia 12, 1553 (1998) | Proteasome activities decrease during dexamethasone-induced apoptosis of thymocytes: J. Beyette, et al.; Biochem. J. 332, 315 (1998) | JNK (c-Jun N-terminal kinase) and p38 activation in receptor-mediated and chemically-induced apoptosis of T-cells: differential requirements for caspase activation: M. MacFarlane, et al.; Biochem. J. 348, 93 (2000) | Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes: W.R. Coward, et al.; J. Immunol. 176, 5284 (2006) | Broad-spectrum caspase inhibitors: from myth to reality? D. Chauvier, et al.; Cell Death Differ. 14, 387 (2007) | A calpain-like protease inhibits autophagic cell death: D.T. Madden, et al.; Autophagy 3, 519 (2007) | Malarial hemozoin is a Nalp3 inflammasome activating danger signal; C. Dostert, et al.; PLoS One 4, e6510 (2009) | Kinesin light chain-4 depletion induces apoptosis of radioresistant cancer cells by mitochondrial dysfunction via calcium ion influx: J.H. Baek, et al.; Cell Death Dis. 496, (2018)
Related Products
| Product Name | Product Code | Supplier |
|---|